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ABSTRACT
Background  
In patients with end stage renal disease and atrial fibrillation (AF), undergoing chronic dialysis, direct 
oral agents are contraindicated and warfarin does not fully prevent embolic events while increasing the 
bleeding risk. The high hemorrhagic risk represents the main problem in this population. Aim of the study 
was to estimate the safety and efficacy for thromboembolic prevention of left atrial appendage (LAA) 
occlusion in a cohort of dialysis patients with AF and high hemorrhagic risk.
Methods 
Ninety-two dialysis patients with AF who underwent LAA occlusion were recruited. For comparative 
purposes, two cohorts of dialysis patients with AF, one taking warfarin (oral anticoagulant therapy, OAT 
cohort, n=114) and the other not taking any OAT (No-Therapy cohort, n=148) were included in the study. 
Primary endpoints 1) incidence of peri-procedural complications, 2) incidence of two-year 
thromboembolic and hemorrhagic events, 3) mortality at two years. In order to evaluate the effect of the 
LAA occlusion on the endpoints with respect to the OAT and No-therapy cohorts, a multivariable Cox 
regression model was applied adjusted for possible confounding factors.
Results 
The device was successfully implanted in 100% of cases. Two major peri-procedural complications were 
reported. No thromboembolic events occurred at two-year follow-up. The adjusted  multivariable Cox 
regression model showed no difference in bleeding risk in the OAT compared to the LAA occlusion 
cohort in the first 3 months of follow-up [HR 1.65(95%CI: 0.43-6.33)], when most of patients were taking 
two antiplatelet drugs. In the following 21 months the bleeding incidence became higher in OAT patients 
[HR 6.48(95%CI: 1.32-31.72)]. Overall mortality was greater in both the OAT [HR 2.76(95%CI: 1.31-
5.86)] and No-Therapy [HR 3.09(95%CI: 1.59-5.98)] cohorts compared to LAA occlusion patients.
Conclusions 
The study could open the way to a non-pharmacological option for thromboembolic protection in dialysis 
patients with AF and high bleeding risk.
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INTRODUCTION 
Non valvular atrial fibrillation (AF) is the most common cardiac arrhythmia in the general population. The 
main complications of AF are stroke and increased risk of death. Oral anticoagulant therapy (OAT) is 
the cornerstone for the management of AF patients at high risk of stroke. 
Current guidelines suggest treatment with Vitamin K Antagonists (VKAs) or Direct Oral Anticoagulants 
(DOACs) for stroke prevention in AF patients with a thromboembolic risk score (CHA2DS2VASc score) 
of at least 1 in males and at least 2 in females [1].
Patients with end stage renal disease (ESRD) undergoing dialysis have a high prevalence and incidence 
of AF [2]. Moreover, AF is associated to increased mortality in this population [2]. Indeed, VKAs fail to 
demonstrate a clear benefit for stroke prevention in these patients, and some studies have raised 
concerns about the possibility that VKAs may generate more harm than benefit [3-5]. Moreover, dialysis 
patients have a higher risk of bleeding due to platelet function alterations associated with uremia [6].
Increased mortality due to hemorrhagic events has been shown in US dialysis patients taking DOACs 
[7] and European cardiology guidelines suggest to avoid routine use of DOACs in patient with severe 
renal dysfunction [8].  
In the last years, Left Atrial Appendage (LAA) occlusion has emerged as an alternative option to OAT 
for AF patients who are at high thromboembolic risk [9]  and not suitable for OAT and recent cardiology
guidelines state that LAA occlusion should be considered in this subset of patients [10]. Retrospective 
studies suggest the efficacy of LAA occlusion in reducing thromboembolic risk in patients with chronic 
kidney disease (CKD), but very few data are available on outcomes in ESRD patients [11-14]. Recently, 
we reported the design of the study and some preliminary results about feasibility of LAA occlusion in 
dialysis patients [15]. In the present study, we report the outcomes of a long-term follow-up of a relatively 
large dialysis population that underwent LAA occlusion. 
METHODS 
Study design 
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This is an Italian, multi-institutional, prospective, open label, observational study performed according 
to STROBE guidelines. Three independent cohorts were followed and compared: LAA occlusion, oral 
anticoagulant therapy (OAT) and No-Therapy cohorts. The study design and the sample size of the LAA 
occlusion cohort was previously published [15]. 
The study protocol adhered to the 1975 Helsinki Declaration for Ethical Treatment of Human Subjects, 
with local ethics committee approval (Comitato Etico della Provincia di Monza e Brianza, study LAAO-
DIA, 17032016). All involved subjects provided an informed consent to participate and for data 
publication. 
Eligibility criteria were 1) ESRD requiring renal replacement therapy (haemodialysis or peritoneal 
dialysis) 2) documented AF (paroxysmal, persistent or permanent) 3) CHA2DS2VASc score 1 in men 
and 2 in women and HASBLED score 3 or contra-indications for long-term anticoagulant treatment 
(e.g. previous life-threatening bleeding without a reversible cause) 4) age >18 years and informed 
consent to participate in the study. Primary outcomes were 1) incidence of peri-procedural complications 
(stroke, systemic thromboembolism, bleeding, pericardial effusion, displacement of the device, cardiac 
tamponade and death) within 30 days of the procedure 2) cumulative incidence of two-year 
thromboembolic and bleeding events (first event) 3) mortality and cumulative incidence of 
cardiovascular events (first event) at two-years. For comparative purposes, two other cohorts of dialysis 
patients with documented AF, one taking VKAs (OAT cohort) and the other not taking any anticoagulant 
therapy (No-Therapy cohort) were included in the study. Both cohorts derive from the database of a
prospective study previously performed by our group running from October 2010 to December 2014. All 
selected patients fitted the same inclusion criteria as the LAA occlusion cohort, but had not undergone 
the procedure [16,17].
Data collection and definitions 
Data were collected regarding the cause of ESRD, dialysis duration, comorbidities and 
echocardiographic parameters. 
The following comorbidities were collected: arterial hypertension, diabetes mellitus, dyslipidemia, 
peripheral arterial disease, ischemic heart disease, heart failure, chronic pulmonary disease (see 
supplementary material for definitions). 
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The following echocardiography parameters were collected: presence of left ventricular hypertrophy 
(LVH), left ventricular dysfunction, atrial dilation (see supplementary material for definitions). 
Different types of AF were defined in agreement with the European Society of Cardiology (1) (see 
supplementary material for definitions). 
Systemic thromboembolism was collected only if imaging-proven (computed tomographic scan or 
nuclear magnetic resonance) and major bleeding was defined as a fall in hemoglobin level of 2 g/dl or 
more or documented transfusion of at least 2 units of packed red blood cells, or an involvement of a 
critical anatomical site (intracranial, spinal, ocular, pericardial, articular, intramuscular with compartment 
syndrome, retroperitoneal) [18]. 
Different types of AF were defined in agreement with the European Society of Cardiology [1]. In all 
patients, the thromboembolic (CHA2DS2VASc) and hemorrhagic (HASBLED) scores were determined 
to quantify patient-specific risk of thromboembolic and bleeding events [19].
Statistical methods
Baseline covariate distributions were summarized using descriptive statistics (median and range for 
continuous variables, and frequencies for categorical variables). The multinomial logistic regression 
model was used to detect imbalances between baseline covariate distributions. 
Survival distributions were estimated by the Kaplan-Meier method. For the LAA occlusion cohort, all 
times were calculated from the date of the procedure and the survival status was updated on 31 
December 2018. For all cohorts data were right-censored in case of last date of follow-
death. Based on the completeness index (C) of follow-up the comparison and treatment effects 
estimates were limited to the first two years of follow-up, and were assessed using the log-rank test and 
the Cox regression model, respectively.  
Multivariable Cox regression models. 
Results of the Cox models are expressed in terms of estimated hazard ratios (HR), 95% confidence 
intervals (95% CI) and p-values. When evaluating first bleeding event as outcome, the proportional 
hazard assumption was not satisfied; we accounted for that by splitting time in two periods (before and 
after 3 months), as many of patients who underwent to LAA occlusion were taking two antithrombotic 
drugs during the first 3 months after the procedure. A backward selection procedure was applied to the 
multivariable Cox models. The full models used as predictors those variables that were significant ly 
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different at the 0.20 level in the univariate analysis comparing the three cohorts  (refer to Table 1). (refer 
to Table 1). Patient cohorts were forced into the multivariable Cox models. 
Sensitivity analysis 
A propensity score analysis was used to control overfitting. In order to evaluate the effect of the LAA 
occlusion on different outcomes, with respect to the reference cohorts we  created a pseudo-
population (that mimics a randomized trial) by the use of (stabilized) inverse probability of treatment 
(and censoring) weights (IPTW) computed by a multivariable logistic model on the propensity to 
undergo LAA occlusion. The weighted Cox regression model with robust standard error was applied to 
the IPTW cohort to assess the effect of LAA occlusion on the different endpoints(see supplementary 
material, Expanded statistical methods).
Multivariable Cox regression model
Statistical analysis was generated using SAS software for Windows, version 9.4 (Cary, NC: SAS Institute 
Inc; 2014). Kaplan-Meier plots were obtained using STATA software for Windows, version 15.1 
(StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). 
(see supplementary material for expanded statistical methods) 
RESULTS 
Ninety-two consecutive patients who had undergone LAA occlusion in 11 Italian participating centers 
between May 2014 and December 2018 were enrolled in the study. The reference cohorts were 
composed of 114 (OAT cohort) and 148 (No-Therapy cohort) patients, respectively. Table 1 shows the 
clinical characteristics of the three cohorts. LAA occlusion patients were more frequently males than No-
Therapy patients and had a shorter dialytic age compared to other cohorts. The prevalence of 
paroxysmal AF was higher in LAA occlusion compared to OAT cohort, while the prevalence of 
permanent AF was higher in LAA occlusion than in No-Therapy patients. Moreover, patients who 
underwent the procedure more often had a previous bleeding and showed higher HASBLED and lower 
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CHA2DS2VASc scores. Antiplatelet prescription was more frequent in LAA occlusion than in OAT 
patients.  Results after IPTW are shown in Supplementary Tables 1 and 2. The median follow-up 
duration was 1.73 (IQR 0.71-2.58) years for the LAA occlusion cohort and 4.0 (IQR 4.00-4.00) years for 
both the OAT and No-Therapy cohorts. The C index at two years was 67%, 98% and 98% for LAA 
occlusion, OAT and No-Therapy cohorts, respectively.  
Peri-procedural complications 
Three types of devices were used: 42 Amplatzer-Amulet (St. Jude Medical Inc., St. Paul, MN, USA), 47 
Watchman (Boston Scientific, Plymouth, MN, USA) and 3 LAmbre [Lifetech Scientific (Shenzhen) Co. 
Ltd., Shenzhen, China]. All devices were implanted successfully. Two non-significant (2.5 and 3 mm) 
post-procedure para-prosthetic leaks were reported. Two major peri-procedural complications were 
recorded: a hemorrhagic pericardial effusion leading to cardiac tamponade (LAmbre device) and an
acute lower limb ischemia due to rupture of the femoral artery (Watchman device). Furthermore, two 
hematomas occurred at the vascular access site. No episodes of thrombosis of the device were 
reported. 
Thromboembolic and hemorrhagic events 
During follow-up, 2 (2.2%), 8 (7.0%), 16 (10.8%) thromboembolic events occurred in the LAA occlusion, 
OAT and No-Therapy cohorts, respectively. Univariate analysis (Kaplan-Meier curves and log-rank test) 
showed no difference in the incidence of thromboembolic events in the LAA occlusion vs OAT cohort 
[2-year estimate of 0 vs 3.9% (95%CI 1.5-10.1); p=0.092], while the incidence was significantly lower in 
the LAA occlusion cohort vs the No-Therapy cohort [2-year estimate of 0 vs 8.0% (95%CI 4.3-14.6) 
p=0.021]. (Figure 1, Panel A).  
For what regards hemorrhagic events (first event), 8 (8.7%), 27 (23.7%), 24 (16.2%) episodes occurred 
in the LAA occlusion, OAT and No-Therapy cohorts, respectively. No differences were observed 
between bleedings in the three cohorts [2-year estimate of 10.6% (95%CI 5.3-20.5) for LAA occlusion, 
19.5% (95%CI 12.4-29.9) for OAT and 16.7% (95%CI 11.1-24.6) for No-Therapy; p=0.474 and p=0.460 
vs LAA occlusion] (Figure 1, Panel B). In the LAA occlusion cohort, 6 out of 8 bleeding episodes occurred 
in the first three months after the procedure. The multivariable Cox regression model for hemorrhagic 
events did not show any differences among the three cohorts in the first three months [HR 1.65 (95%CI 
0.43-6.33) OAT vs LAA occlusion and HR 0.57 (95%CI 0.18-1.84) No-Therapy vs LAA occlusion]. 
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However, the risk of bleeding in the following 21 months was significantly higher in both OAT [HR 6.48 
(95%CI 1.32-31.72)], and No-Therapy patients [HR 4.87 (95%CI 1.08-21.97)] compared to LAA 
occlusion patients (Table 2). The sensitivity analysis confirmed the result of the multivariable Cox model, 
with the exception of the risk of bleeding in months 4-24, which was not different between the LAA 
occlusion cohort and the No-Therapy cohort (supplementary Table 3). The results were unchanged after 
excluding PD patients from the study population (supplementary Table 4). The multivariable Cox model 
was not applied for the evaluation of thromboembolic events as no events occurred in the first 2 years 
in the LAA occlusion cohort. In the LAA occlusion cohort, the median thromboembolic (CHA2DS2VASc) 
and hemorrhagic (HASBLED) scores were 4.0 (range 2-8) and 4.0 (range 3-6), respectively and  the 
number of observed events was lower than the number of expected events according to the scores [1.4 
(95%CI 0-2.8) vs 4.0/100 patient years for thromboembolism, p<0.001 and 5.5 (95%CI 0-28.0) vs 
8.7/100 patient years for bleeding, p=0.808] (Figure 2). 
Mortality and cardiovascular events 
During follow-up, 17 (18.5%), 67 (58.8%), 94 (63.5%) deaths occurred in the LAA occlusion, OAT and 
No-Therapy cohorts, respectively. Overall survival was significantly higher in LAA occlusion patients 
compared to the other cohorts [2-year estimate of 77.7% (95%CI 64.1-86.6) for LAA occlusion, 57.0% 
(95%CI 47.3-65.6) for OAT and 56.0% (95%CI 47.5-63.6) for No-Therapy; LAA occlusion vs OAT 
p=0.009 and LAA occlusion vs No-Therapy p=0.003] (Figure 1, Panel C). Nonfatal cardiovascular events 
occurred 20 (21.7%), 68 (59.6%), 77(52.0%) times in the LAA occlusion, OAT and No-Therapy cohorts, 
respectively and their incidence was lower in LAA occlusion patients compared to the other cohorts [2-
year estimate of 27.9% (95%CI 17.8-42.0) for LAA occlusion, 57.2% (95%CI 47.6-67.2) for OAT and 
53.8% (95%CI 44.9-63.2) for No-Therapy; LAA occlusion vs OAT p<0.001 and LAA occlusion vs No-
Therapy p< 0.001] (Figure 1, Panel D). 
In the multivariable Cox model overall mortality was significantly higher in both OAT [HR 2.76 (95%CI 
1.31-5.86)] and No-Therapy [3.09 (95%CI 1.59-5.98)] cohorts in comparison with LAA occlusion 
patients. The risk of nonfatal cardiovascular events was higher in patients taking warfarin or taking no 
OAT than in patients who had undergone the procedure [HR 5.07 (95%CI 2.49-10.34) OAT vs LAA 
occlusion and HR 3.11 (95%CI 1.78-5.42) No-Therapy vs LAA occlusion] (Table 2). The sensitivity 
analysis confirmed all the results of the multivariable Cox models (supplementary Table 3). The results 
were unchanged after excluding PD patients from the study population (supplementary Table 4). 
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Post-procedural antithrombotic therapy 
Each center participating in the study was free to choose the post-procedural therapy considered most 
suitable for the patient. The majority of patients were discharged from the hospital with a two drugs 
prescription (n=65, 70.6%), to be taken for 1 (n=10, 15.4%), 3 (n=29, 33.8%) or 6 (n=8, 12.3%) months. 
The remaining 18 (16.6%) patients continued the therapy with two drugs for more than 6 months. A fair 
percentage of patients were discharged taking only one drug (n=21, 22.8%) and, in subjects with a 
particularly high risk of bleeding, no therapy was prescribed (n=2, 2.2%). Only one patient took three 
drugs for a month. Supplementary Table 5 shows the post-procedural therapies taken by patients 
undergoing LAA occlusion.
DISCUSSION 
The study suggests that LAA occlusion is not only feasible and safe in patients undergoing dialysis, but 
that, in the long term, it is also associated with a reduction of thromboembolic events compared to non-
treated patients, and of haemorrhagic events compared to patients taking OAT. Furthermore, in our 
population, two-year survival is significantly higher in the cohort of patients who underwent the 
procedure and the incidence of nonfatal cardiovascular events is significantly lower, compared to both 
the OAT and No-Therapy cohorts. 
Few data are available about LAA occlusion outcomes in CKD patients. Case reports in ESRD dialysis 
patients, retrospectively collected, have been described (10-12). A retrospective analysis of patients 
undergoing the procedure  showed that CKD patients, when compared to non-CKD patients, had a 
greater number of events at follow-up and a higher risk of acute renal failure associated with the 
procedure [20]. Some additional information was provided by data from a large registry, which included 
19 out of 1014 patients with stage 5 CKD, 14 of whom undergoing dialysis [11]. In this analysis, dialysis 
patients were merged with those with stage 4 and 5 CKD not on dialysis and a significant reduction in 
stroke and bleeding compared to the expected annual risk was observed. Recently, Gotzmann et al. 
retrospectively analysed 128 patients and showed that the incidence of mortality, bleeding or 
thromboembolism was not significantly higher in the subgroup of 33 patients with ESRD [21].
To our knowledge, this is the first prospective, multicenter study designed to evaluate the efficacy and 
safety of LAA occlusion in a relatively large sample of patients with ESRD. In our study the number of 
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thromboembolic events in LAA occlusion patients is lower compared to the No-Therapy cohort. In the 
first two years of follow-up, no event is observed in patients who underwent the procedure compared 
to an incidence of 4% in OAT patients and 8% in patients not taking therapy. Furthermore, long-term 
hemorrhagic events are significantly less frequent in LAA occlusion patients than in both the cohort 
taking OAT, and the No-Therapy cohort (10.6%, 19.5% and 16.7% at two years, respectively). 
Moreover, in LAA occlusion patients, the incidence of thromboembolic events and of bleeding is less 
than expected based on CHA2DS2VASc and HASBLED scores. The difference in bleeding risk 
between the LAA occlusion and the OAT cohorts becomes evident by excluding the events occurring 
in the first three months after the procedure from the analysis, when more than 70% of the patients 
received the prescription of at least two anticoagulant drugs. The therapeutic attitude shown in our 
study is similar to that reported in non-CKD patients [22], however the excess of early bleeding should 
lead us to reconsider whether it is really necessary, in patients with such a high risk of bleeding, to 
take two drugs rather than one after the procedure.In fact, there are many doubts about the use of 
dual antiplatelet agents in dialysis patient even in the presence of other clinical situations, such as 
ischemic heart disease [23]. Recently, even among cardiologists, the need to always prescribe double 
antiplatelet therapy after LAA occlusion has been questioned, and several registry data suggest that 
single antiplatelet therapy is just as effective as double antiplatelet therapy [24-27].
An unexpected finding is the reduction in mortality and nonfatal cardiovascular events in the LAA 
occlusion cohort compared to the other two cohorts. A similar finding has been previously observed in 
the Protect-AF trial [9]. There are several data showing a better survival in dialysis patients with AF
taking OAT, compared to those not taking therapy [16,28]. In our study, LAA occlusion seems to offer 
an additional survival advantage. In patients who underwent LAA occlusion no deaths due to neither 
ischemic nor haemorrhagic stroke occurred, but this is not enough to justify such an important advantage 
in terms of survival in the LAA occlusion cohort. One hypothesis could be that patients undergoing the 
procedure are followed with particular attention by an interdisciplinary team of physicians (cardiologists 
and nephrologists), with the consequence that any clinical problem is addressed by both specialists as 
soon as it becomes evident. If this is true, the study would further underline the importance of close 
collaboration between cardiologists and nephrologists in treating nephrological patients presenting 
cardiological diseases.  
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The number of peri-procedural complications of our patients is relatively low, although not negligible, 
and comparable to that reported in cardiology populations without renal disease that underwent the 
procedure [29,30]. Probably this favourable safety profile is due to the participation in our study only of 
skilled operators, very confident with the procedure. Though this could constitute a barrier to the 
spread of LAA occlusion for thromboembolic prevention in dialysis patients, we believe it is very 
important to consider this option in this population only if a team of experienced cardiologists, who 
have already performed a large number of procedures, is available. Another problem for the diffusion 
of the procedure could be its cost. However, a recent study has shown that LAA occlusion  proved to 
be not only cost-effective, but cost saving relative to warfarin and DOACs [31]. 
Using DOACs in patients with ESRD remains an open problem. An observational study recently 
suggested an advantage in terms of efficacy and safety of using DOACs in hemodialysis patients with 
AF [32]. Achieving positive results from CRTs that compare VKAs and DOACs in ESRD patients would 
be very important, because it would offer a new therapeutic opportunity to the population of dialysis 
patients with AF. There are currently two ongoing CRTs to test the safety of apixaban in this population 
(AXADIA trial, NCT02933697 and RENAL-AF trial, NCT02942407). The preliminary results of the 
RENAL-AF trial have been disappointing. The study was terminated prematurely and showed similar 
rates of bleeding with apixaban and warfarin [33]. We are waiting for the results of the AXADIA trial, but 
at present no studies are available to support the hypothesis that DOACs represent an advantage for 
thromboembolic prevention over warfarin in ESRD patients with AF [34]. LAA occlusion therefore is an 
option to be taken into consideration for subjects with advanced CKD and particularly high bleeding risk. 
Our study has some strengths and some limitations. Strengths are the sample size, the prospective 
design of the study and the fact that a comparison was made between the population of patients who 
underwent the procedure and two other populations with similar clinical characteristics. A limitation is 
that it is not a controlled and randomized study. However, we think that it would not be ethical neither to 
randomly assign patients with such a high risk of bleeding to OAT treatment nor to assign patients with 
a high risk of thromboembolic events to a treatment arm without any antithrombotic therapy. Despite the 
rigorous statistical approach used in the present study, however, we cannot exclude that physicians 
proposed the LAA occlusion procedure mainly to patients who seemed less frail. If this were the case, 
however, the result regarding the feasibility, efficacy and safety of the procedure would, in our opinion, 
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remain valid. A Spanish study is currently underway in ESRD patients (WATCH-HD, NCT03446794) 
which includes two arms, watchman device vs no-therapy. The study is still under recruitment. 
In conclusion, our study could open the way to a non-pharmacological option for thromboembolic 
protection in a fragile category of AF patients, which otherwise would be destined not to take OAT or to 
take it exposing themselves to a high risk of bleeding. 
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Figure legends 
Figure 1: Incidence of thromboembolic (Panel A) and hemorrhagic (Panel B) events; and overall 
survival (Panel C) and incidence of cardiovascular events (Panel D), estimated by Kaplan-Meier 
curves, in the three cohorts of patients. 
Figure 2: Expected and observed hemorrhagic and thromboembolic events according to 
CHA2DS2VASc and HASBLED scores in the LAA occlusion cohort. 
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Table 1.  
Clinical characteristics and comorbidities of the study population 
Cohort Odds Ratio
LAA
Occlusion
N=92
OAT
N=114
No Therapy
N=148
OAT
No 
Therapy
P-value
Gender
Male N (%) 71 (77.2) 75 (65.8) 83 (56.1) 0.57 0.38 0.004
Age
Yrs (median [IQR])
>= 75 yrs
N (%)
74 [76,80]   
42 (45.7)
76
[71,80]
64 (56.1)
76 [69, 82]
85 (57.4)
1.03
1.52
1.03
1.61
0.043
0.177
Dialytic age
>= 3 yrs
Missing data
N (%) 34 (38.2) 66 (57.9) 85 (57.4) 2.22 2.18 0.007
N (%) 3 (3.3) 0 0
BMI kg/m2 N 75 97 126 1.00 0.97 0.269
Median 25.0 24.5 23.3
Min-max 14.0-42.0 3.0-44.0 1.0-49.1
Current smoking
Yes
Missing data
N (%) 6 (6.7) 12 (11.3) 17 (12.9) 1.77 2.04 0.351
N (%) 3 (3.3) 8 (7.0 ) 16 (10.8)
CHA2DS2VASc
Score (median [IQR]) 4 [3,5] 4 [4,5] 5 [3,6] 1.36 1.35 0.001
HASBLED
Score (median [IQR]) 4[4,5]                       4 [3,5] 4[4,5] 0.66 0.87 0.050
Atrial Fibrillation
Permanent N (%) 43 (46.7) 60 (52.6) 33 (22.3) 1 <0.001
Persistent N (%) 15 (16.3) 42 (36.8) 72 (48.6) 2.01 6.25
Paroxysmal N (%) 34 (37.0) 12 (10.5) 43 (29.1) 0.25 1.65
Comorbidities
LAA: Left Atrial Appendage; OAT: Oral Anticoagulant Therapy; na: not available; nd: not determined 
Hypertension N (%) 82 (89.1) 95 (83.3) 131 (88.5) 0.61 0.94 0.368
Diabetes mellitus N (%) 33 (35.9) 36 (31.6) 50 (33.8) 0.83 0.91 0.809
Dyslipidemia N (%) 49 (53.3) 45 (39.5) 41 (27.7) 0.57 0.34 <0.001
Peripheral artery disease N (%) 50 (54.3) 83 (72.8) 101 (68.2) 2.25 1.81 0.017
Ischaemic heart disease N (%) 43 (46.7) 56 (49.1) 75 (50.7) 1.10 1.17 0.839
Heart failure N (%) 32 (34.8) 49 (43.0) 54 (36.5) 1.41 1.08 0.419
Ischaemic stroke N (%) 9 (9.8) 12 (11.4) 9 (6.7) 1.19 0.66 0.431
Missing data N (%) 0 (0) 9 (7.9) 13 (8.8)
Chronic pulmonary disease N (%) 18 (19.6) 21 (18.4) 30 (20.3) 0.93 1.05 0.932
Thromboembolic pulmonary 
disease
N (%) 2 (2.2) 1 (0.9) 5 (3.4)
0.40 1.57 0.444
Bleeding N (%) 56 (60.9) 15 (13.2) 36 (24.3) 0.10 0.21 <0.001
Echocardiography
Atrium dilatation N (%) 78 (87.6) na na nd nd nd
Missing data N (%) 3 (3.3) 114 (100) 148 (100)
Left ventricular ejection fraction 
< 50%
N (%) 19 (20.9) 28 (25.9) 38 (28.1)
1.33 1.48 0.467
Missing data N (%) 1 (1.1) 6 (5.3) 13 (8.8)
Left ventricular hypertrophy N (%) 44 (57.1) 67 (61.5) 82 (61.2) 1.20 1.18 0.808
Missing data N (%) 15 (16.3) 5 (4.4) 14 (9.5)
Antiplatelet N (%) 59 (64.1) 32 (28.1) 104 (70.3) 0.22 1.32 <0.001
Heparin N (%) 31 (33.7) 33 (28.9) 30 (20.7) 0.80 0.51 0.075
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